💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Risankizumab

CHEMBL3990029 Phase 4 承認済み Antibody
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Risankizumab is a humanized monoclonal antibody that selectively binds the p19 subunit of interleukin-23 (IL-23), blocking its interaction with the IL-23 receptor and preventing downstream Th17 cell differentiation and pro-inflammatory cytokine production. It is approved for the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis, moderate-to-severe Crohn's disease, and moderate-to-severe ulcerative colitis.

治療領域

Asthma Inflammatory Bowel Disease Psoriasis Atopic Dermatitis

作用機序

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

Risankizumab is a humanized monoclonal antibody that selectively binds the p19 subunit of interleukin-23 (IL-23), blocking its interaction with the IL-23 receptor and preventing downstream Th17 cell differentiation and pro-inflammatory cytokine production. It is approved for the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis, moderate-to-severe Crohn's disease, and moderate-to-severe ulcerative colitis.

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Yes, Risankizumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3990029. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.